VEGFA and diabetic macular edema: Moreover, we must not overlook the fact that the DEX implant, both in RVO and diabetic macular edema, represents the first-line treatment in all those patients who may not be suitable for repeated anti-VEGF treatments, such as patients with high-risk cardiovascular disease or who are unable to attend monthly or frequent appointments, with poor compliance, severe macular edema (more than 500 microns), history of cataract surgery, and scheduled for cataract surgery [94,98,99].